Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical Developments International (MVP) has announced positive results from multiple studies completed using its pain-reducing drug
  • The self-administered drug is commonly used by patients who are undergoing procedures and has already received sales of more than 5 million
  • Tests have shown the drug to have superiority over already existing treatments
  • MVP’s share price is up 12 per cent, with shares trading for $5.79 apiece

Medical Developments International (MVP) has announced positive results from testing Penthrox.

Penthrox is a fast onset, non-opioid analgesic that is indicated for pain relief by self-administration in patients who require pain killers for surgical procedures.

The product has been used for more than 40 years in Australia and more than five million units of it have been sold.

There is a growing interest in Penthrox being used in patients who are undergoing investigatory procedures and operational procedures such as a colonoscopy.

This most recent study demonstrated that Penthrox has superiority over intravenous (directly into a vein) morphine, paracetamol, ketoprofen, and non-steroidal anti-inflammatory drugs (NSAIDS) within a trauma setting.

When added to a standard of care, Penthrox shows dominance over placebo in a trauma setting.

Penthrox was shown to be successful in dislocation injuries and resulted in less time spent in emergency departments thus improving patient experience and reducing crowding.

Other studies confirmed that Penthrox is effective, well tolerated and rapidly acting in trauma settings.

Studies completed show that Penthrox exceeded both patient and clinician expectations and resulted in a high degree of treatment satisfaction from patients and health care professionals.

While some people tolerated Penthrox, the most adverse event that was experienced was mild and temporary.

MVP CEO John Sharman is pleased with the results received from trials of Penthrox.

“We are delighted with the results of these recent European clinical trials demonstrating the superiority of Penthrox over standard of care treatments (intravenous, morphine, IV, paracetamol, ketoprofen or NSAIDS),” John said.

“This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication,” he added.

Shares in MVP are up 12 per cent and trading for $5.79 a share in a $379.8 million market cap.

MVP by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.